Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Prospects for the development of immunosuppressive drugs with reduced nephrotoxicity

References

• MORRIS RE: Primer on new small molecule immunosup- pressants. Transplantation Society Bulletin (1993) 1:15-20. An excellent short review covering the new immunosuppressive agents.
   Google Scholar
• THOMSON AW, CARROLL PB, MCCAULEY J, WOO J, ABU- ELMAGD K, STARZL 'FE, VAN THIEL OH: FK506: A novelimmunosuppressant for treatment of autohntuune dis-ease: rational and preliminary clinical exposure at the University of Pittsburgh. Springer Semin. Immunopathol. (1993) 14:323-344. Preliminary clinical experience with FK506 in the treatment of autoimmune disease at the University of Pittsburgh.
   Google Scholar
• MIHATSCI I MJ, THIEL G, RYFFEL B: Morphology of ci-closporin nepbropathy. Prog. Allergy (1986) 38:447–457.
   PubMedGoogle Scholar
• WHITING PIT: Acute and chronic nephrotoxicity associ- ated with immunosuppressive drugs. Curr. Opin. Neph-rot Hypertens. (1994) 3:174-181. A general review highlighting current concepts and controversies and potential treatment options.
   Google Scholar
• BENNETT WM: The nephrotoxicity of inununosuppres- sive drugs. Clin. Neplorol. (1995) 43\(Suppl. 1):S3-S7. A useful, well written short review covering the nephrotoxicity of CsA, cyclosporin analogues, FK506 and rapamycin.
   Google Scholar
• KAHAN BD: Cyclosporine: the base for imnaunosup- pressive therapy - present and future. Transplant. Proc. (1993) 25:508-510. A useful article comparing the immunosuppressive and toxicological properties of cyclosporin and Tacrolimus.
   Google Scholar
• DUMONT FJ, STARUCH MJ, KOPRAK SL, SIEKIERA JJ, LIN CS, HARRISON R, SEWELL T, KINDT VM, BEATrIE TR, VVYVRATT M: The immunosuppressive and toxic effects of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin. J. Exp. Med. (1992) 176:751–760.
   PubMed Web of Science ®Google Scholar
• BENNETT WM, CARPENTER CB, SHAPIRO ME, STROM TB, HEFTY D, TILLMAN M, ABRAMS J, RYAN D, KELLEY VR: Delayed omega-3 fatty add supplements in renal trans-plantation. A double-blind, placebo-controlled study. Transplantation (1995) 59:352-356. The addition of eicosapentanoic acid treatment early in the post transplant period has potential benefits with respect to both CsA nephrotoxicity and the incidence of rejection episodes. KOVAR 1K 3, MUELLER EA, VAN BARE JB, FLUCICIGER SS, LANGE H, SCHMIDT B, BOESKEN WH, LISON AE, KLITZ K: Cyclosporine pharmacokittetics and variability from a microemulsion formulation - a multicenter investiga-tion in kidney transplant patients. Transplantation (1994) 58:658–663.
   Google Scholar
• MUELLER EA, KOVARIC J, VAN BREE JB, LISON AE, KUTZ K: Pharmacokinetics and tolerability of a microemul-sion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation (1994) 57:1178-1182. A comparison of Sandirnmun and Neoral pharmacokinetics in renal allograft recipients.
   Google Scholar
• BURDMANN EA, ROSEN S, LINDSLEY J, ELZINGA L, ANDOHT, BENNETT WM: Renal and hepatic effects of cyclospor-ine G vs. cyclosporine A in experimental chronic neph-rotoxicity. J. ASN (1992) 3:841.
   Google Scholar
• HIESTAND PC, GRABER M, HURTENBACH U, HERMANN P,CAMMISULIS S, RICHARDSON BP, EBERLE MK, DONATSCH P, RYFFEL B, BORELJF: New cyclosporine derivative SDZ IND1 125: in vitro and in vivo pharmacological effects and toxicological evaluation. Transplant. Proc. (1993) 25:691.
   PubMedGoogle Scholar
• HENRY ML, TEST RJ, ELKHAMMAS EA, FERGUSON RMI A randomized, prospective, double blinded trial of cy-closporine vs. 0G37-325 in cadaveric renal transplan-tation - a preliminary report. Transplantation (1993) 55:748-752. The findings suggest that CsA and CsG are associated with similar one year patient and graft survival rates, but that CsG may be associated with less nephrotoxicity.
   Google Scholar
• HUSER B, THIEL G, OBERHOLZER M, BEVERIDGE T, B1AN- CHI L, MIHATSCH MJ, LANDMANN J: The efficacy and tolerability of cyclosporine G in human kidney trans- plant recipients. Transplantation (1992) 54:65-69. This is the first report of the use of CsG in human renal transplant recipients
   Google Scholar
• TV Y, STEPKOWSKI SM, CHOU T-C, KAHAN BD: The synergistic effects of cyclosporine, sirolimus and bre-quinar on heart allograft survival in mice. Transplanta-tion(1995) 59:177-153. This paper demonstrates admirably the immune synergy displayed by CsA, rapamycin and brequinar sodium administered at sub-therapeutic doses.
   Google Scholar
• STARZL TE: FK506versus cyclosporine. Transplant. Proc.(1993) 25:511-512.10.
   Google Scholar
• JEGASORTHY By, ACKERMAN CD, TODO S, FUNG JJ, ABU-ELMAGD D, STARZL TE: Tacrolimus (FK506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol. (1992) 128:781–785.
   PubMed Web of Science ®Google Scholar
• YAMADA K, SUGISAKA Y, AKIMOTO M, YAMANAKA N: FK506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney - morphologic and biologic analysis. Transplant. Proc. (1992) 24:1396-1398. This study clearly demonstrates the similarities between acute CsA and FK506 nephrotoxicity in the rat.
   Google Scholar
• JAPANESE FK506 STUDY GROUP: Japanese study of FK506 on kidney transplantation: results of late Phase II study. Transplant. Proc. (1993) 25:649-654. The authors suggest that graft biopsy and regular blood monitoring of FK506 concentrations are essential for patient management.
   Google Scholar
• WHITING PH, WOO J, ADAM BJ, HASAN NU, DAVIDSONRJL, THOMSON AW: Toxicity of rapamycin - a compara-tive and combination study with cyclosporine at 11:1111111-notherapeutic dosage in the rat. Transplantation (1991) 52:203–208.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, CHANG JY, SEHGAL SN: Precfinical evalu-ation of a new potent imrnunosuppressive agent, ra-pamycin. Transplantation (1991) 52:185–191.
   PubMed Web of Science ®Google Scholar
• BURDMANN EA, ANDOII TF, FRANCESCHINI N, LINDSLEYJ, VORA J, BENNETT WM: Renal and metabolic effects of short-term rapamycin (RAPA) treatment in salt-de-pleted rats.]. Am. Soc. Nepbrol. (1993) 4:910.
   Google Scholar
• GRANGER DK, CROMWELL JW, CHEN SC, GOSWITZ JJ, MORROW DT, BEIERLE FA, SEHGAL SN, CANAFAX DM, MATAS AJ: Prolongation of renal allograft survival in a large animal model by oral rapamycin therapy. Trans-plantation (1995) 59:183-186. A well designed study demonstrating the immunoefficacy of rapamy-cin monotherapy.
   Google Scholar
• THLIVERIS JA, SOLEZ K, YATSCOFF RW: A comparison of the effects of rapamycin and cyclosporine on kidney and heart morphology in a rabbit heterotopic heart transplant modeL His!. Histopath. (1995) 10:417–421.
   Web of Science ®Google Scholar
• ANDOH TF, LINDSLEY J, BENNETT WM: Cyclosporine (CsA) and rapamycin (RAPA) are synergistic for chronic nephrotoxicity in rats. J. Am. Soc. Nepbrot (1995) 6:1054. Preliminary results which suggest that the CsA and rapamycin synergism for chronic nephrotoxicity may be causally related to abnormal glucose homeostasis.
   Google Scholar
• SOLLINGER FIW, BELZER FO, DEIERHOI MH, DIETHELM AG, GONWA TA, KAUFFMAN RS, KLINTMALM GB, MCDIARMID SV, ROBERTS J, ROSENTHAL JT, TOM-LANOVICH SJ: RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant re-jection. Ann. Sur. (1992) 216:513–519.
   PubMed Web of Science ®Google Scholar
• DEIERHOI MH, SOLLINGER HW, DIETHELM AG, BEIZER FO, KAUFFMAN RS: One-year follow-up results of a Phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant. Proc. (1993) 25:693–694.
   PubMed Web of Science ®Google Scholar
• KLINTMALM GB, ASCHER NL, BUSUTTIL RW, DEIERHOI M,GONWA TA, KAUFFMAN R, MCDIARMID S. POPLAWSKI S, SOLLINGER H, ROBERTS J: RS-61443 for treatment-resis-tant human liver rejection. Transplant. Proc. (1993) 25:697.
   Google Scholar
• AMEMIYA H, TAGUCHI Y, FUKAO K, ISONO K, OMOTO R,OTA K, KOSAKI M, TAKAGI H, OKA T, SONODA T, ORITA K, DOHI K: Establishment of rejection therapy with deoxyspergualin by multicentral controlled clinical studies in renal recipients. Transplant. Proc. (1993) 25:730–733.
   PubMed Web of Science ®Google Scholar
• HOLLANDER AAMJ, VAN SAASE JLCM, K001 1E AMM, VANDORP WT, VAN BOCKEL HJ, VAN ES LA, VAN DER WOUDE FJ: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet (1995) 345:610–614.
   PubMed Web of Science ®Google Scholar